PD 166793 inhibits MMPs, enzymes that degrade extracellular matrix components, thus having potential therapeutic applications in cancer and chronic inflammatory diseases. It targets MMP-1, MMP-13, MMP-2, MMP-3, MMP-7, and MMP-9.
PD 166793 is relevant in cardiovascular research, particularly in inhibiting enzymes that degrade matrix components during heart failure and restenosis.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
